Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01837667
Title Phase I Study of LB-100 With Docetaxel in Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Lixte Biotechnology Holdings, Inc.

Advanced Solid Tumor


Docetaxel + LB-100

Age Groups: adult
Covered Countries USA

No variant requirements are available.